Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 4/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CHRND | Q07001 | 6/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.42 |
| ▸ | CHRNG | P07510 | 2/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22857298 | 0.87 | MMP8 (0.43) | GRIA1MMEACECPA1ACE2 | |
| SCHEMBL16846635 | 0.86 | GRIA1 (0.46) | GRIA1MMEACECPA1ACE2 | |
| SCHEMBL18879461 | 0.85 | GRIA1 (0.44) | GRIA1MMEACECPA1ACE2 | |
| SCHEMBL10078064 | 0.76 | ESR1 (0.53) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL12869808 | 0.76 | FOLH1 (0.61) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL5738141 | 0.76 | FOLH1 (0.61) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL23306918 | 0.76 | ACE (0.50) | GRIA1MMEACECPA1ACE2 | |
| SCHEMBL12894465 | 0.75 | ACE (0.52) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL7601953 | 0.75 | FOLH1 (0.49) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL27250348 | 0.75 | FOLH1 (0.49) | MMEACECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200224198-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | GRIA1 2989/4885MME 3457/4885ACE 3635/4885 |
| US-20190127737-A1 | SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III | APOB, APOL1, RBM3 | GRIA1 4650/4885MME 915/4885ACE 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.